C

P

CHINET-CHARROT , Paule

Last name: CHINET-CHARROT

First name: Paule

July 2015 (v1)

Journal article

Metadata-only

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Fizazi, Karim Faivre, Laura Lesaunier, François

BACKGROUND:Early risk-stratified chemotherapy is a standard treatment for breast, colorectal, and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and estramustine improves survival in patients with castration-resistant prostate cancer. We assessed the effects of combined docetaxel and estramustine on relapse in...

Uploaded on: December 4, 2022
2023 (v1)

Journal article

Metadata-only

Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial

Orlando, Valentina Drubay, Damien Lavaud, Pernelle

Introduction: Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases is not fully established. Patients and Methods: Ancillary analysis from the GETUG 12 phase 3 trial. Patients with non-metastatic high-risk...

Uploaded on: December 25, 2023